Drupal.behaviors.print = function(context) {window.print();window.close();}>

Tekmira Official Defends apoB as Cholesterol Target, Touts RNAi Rx Over Isis Antisense Candidate

August 13, 2009

Tekmira Official Defends apoB as Cholesterol Target, Touts RNAi Rx Over Isis Antisense Candidate

Tekmira also released its second-quarter financial results, posting decreased losses on higher revenues.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories